Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trimetazidine for Coronary Microvascular Dysfunction in INOCA
NCT03504202Unknown
- Sponsor
- Shanghai Tenth People's Hospital
- Start
- Mar 2019
- Primary completion
- Apr 2020
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of trimetazidine in Coronary Microvascular Dysfunction (CMD), sponsored by Shanghai Tenth People's Hospital. Primary endpoint: Coronary Flow Reserve at 6 months. Status: unknown.
02
Drugs
trimetazidine
03
Conditions
Coronary Microvascular Dysfunction (CMD)
Beyond the preview
Go deeper on NCT03504202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03504202.